Invivyd (IVVD) Non-Current Assets (2021 - 2026)
Invivyd's (IVVD) quarterly Non-Current Assets came in at $29.4 million in Q4 2025, up 2.02% YoY from $28.8 million in Q4 2024, and little changed on a QoQ basis from $29.4 million in Q3 2025.
Invivyd (IVVD) Non-Current Assets (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Non-Current Assets data on file, last reported at $29.4 million in Q4 2025.
- Quarterly Non-Current Assets rose 2.02% year-over-year to $29.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $116.6 million (up 135.16% YoY) and the FY2025 annual result came in at $29.4 million, up 2.02% from the prior year.
- Non-Current Assets steadied at $29.4 million in Q4 2025, from $29.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $29.9 million in Q2 2025 to a low of $1.9 million in Q2 2021.
- A 5-year average of $11.2 million and a median of $5.6 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 48.47% — and 2025, when it jumped 588.74%.
- Tracing IVVD's Non-Current Assets over 5 years: stood at $3.4 million in 2021, then surged by 84.91% to $6.2 million in 2022, then sank by 31.2% to $4.3 million in 2023, then jumped by 570.56% to $28.8 million in 2024, then advanced by 2.02% to $29.4 million in 2025.
- The last three Non-Current Assets figures came in at $29.4 million (Q4 2025), $29.4 million (Q3 2025), and $29.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 36.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.77 Mn |
| Dec 31, 2025 | 29.42 Mn |
| Sep 30, 2025 | 29.39 Mn |
| Jun 30, 2025 | 29.86 Mn |
| Mar 31, 2025 | 27.92 Mn |
| Dec 31, 2024 | 28.83 Mn |
| Sep 30, 2024 | 10.82 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 5.59 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 5.43 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 3.15 Mn |
| Jun 30, 2022 | 3.25 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 6.12 Mn |
| Jun 30, 2021 | 1.93 Mn |